Teprotumumab: a disease modifying treatment for graves’ orbitopathy

Teprotumumab: a disease modifying treatment for graves’ orbitopathy

Abstract Background On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves’ orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled clinical trials. Discussion This articl...

Full description

Bibliographic Details
Main Authors: Michelle Ting, Daniel G. Ezra
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Thyroid Research
Subjects:
Teprotumumab
Graves’ orbitopathy
Thyroid eye disease
Proptosis
Monoclonal antibodies
Insulin-like growth Factor-1 receptor
Online Access:http://link.springer.com/article/10.1186/s13044-020-00086-7

Internet

http://link.springer.com/article/10.1186/s13044-020-00086-7

Similar Items